Too many donor kidneys are discarded in U.S. before transplantation

December 15, 2020

PHILADELPHIA - When kidneys are removed from deceased organ donors in the United States, they are often subjected to "procurement biopsies" and are discarded if certain abnormalities are seen in the kidney tissue -- a practice that worsens the already-severe shortage of transplant-eligible kidneys in the country. However, a large portion of the discarded kidneys would function acceptably if transplanted, according to a new study from a team led by researchers in the Perelman School of Medicine at the University of Pennsylvania and the Paris Translational Research Center for Organ Transplantation.

In the study, published today in the Journal of the American Society of Nephrology, the researchers analyzed biopsy data on a series of 1,103 kidneys discarded in the U.S. between 2015 and 2016. They found that 493 of these kidneys could be matched, in terms of biopsy-evaluated quality and other donor characteristics, to 493 kidneys that were actually transplanted in France, where transplant practice is less restrictive.

The researchers then examined the performance of these 493 kidneys transplanted in France, and found that their survival rates were acceptable -- 93 percent at one year, 81 percent at five years, and 69 percent at 10 years -- indicating that many donor kidneys in the U.S. are being discarded unnecessarily.

Analyzing a larger set of kidney transplants in France for which biopsy data were available, the researchers concluded that the biopsy data added no value in terms of making predictions of transplant failure more accurate.

"These results highlight a lost transplant opportunity in the U.S., and provide a strong rationale for organ procurement organizations to reduce the practice of obtaining biopsies of deceased donor kidneys," said study lead author Peter Reese, MD, MSCE, an associate professor of Renal-Electrolyte & Hypertension and Epidemiology in the Perelman School of Medicine at the University of Pennsylvania and a kidney transplant physician at the Penn Transplant Center.

The study was a collaboration involving several medical centers in the U.S., France, and Belgium, co-led by Olivier Aubert, MD, PhD and corresponding author Alexandre Loupy, MD, PhD, of the Paris Translational Research Center for Organ Transplantation.

The shortage of kidneys for transplantation continues to be a public health crisis in the U.S. More than 90,000 patients are waiting for kidney transplants, yet only about 20,000 transplants are performed each year. Annually, nearly 5,000 people on the transplant waiting list die without getting a transplant.

Deceased donors provide roughly two-thirds of transplanted kidneys, but thousands of deceased-donor kidneys are discarded annually in the U.S., due to abnormalities seen in procurement biopsies. Studies suggest that most discards are due to a finding of substantial glomerulosclerosis, a condition that can be caused by age or diabetes, for example, and involves the scarring of small blood vessels in the kidney. However, research also suggests that the reproducibility of procurement biopsy findings is poor.

Moreover, kidney transplants in several European countries are usually done without procurement biopsies and are therefore less likely to be discarded. A study published last year by the same research team found that French transplant centers are much more likely that U.S. centers to accept kidneys from older deceased donors. In fact, the average age of French deceased donors is more than 15 years older than deceased kidney donors in the U.S.

The findings from this new study underscore the notion that pre-transplant biopsies don't seem to add value to the kidney transplant process, and in fact tend to make things worse by reducing the supply of kidneys that could benefit recipients.

"Transplant center staff should understand that procurement biopsy results only contribute limited meaningful information about kidney quality," Reese said. "In some cases, those biopsies may add bad information. And unfortunately, those biopsies come at a cost -- in terms of delays, dollars and occasionally, complications."
-end-
Other co-authors on the study were Maarten Naesens, Edmund Huang, Vishnu Potluri, Dirk Kuypers, Antoine Bouquegneau, Gillian Divard, Marc Raynaud, Yassine Bouatou, Ashley Vo, Denis Glotz, Christophe Legendre, Carmen Lefaucheur, Stanley Jordan, Jean-Philippe Empana, and Xavier Jouven.

Funding was provided by INSERM, Fondation Bettencourt Schueller, the National Kidney Foundation, and the U.S. Department of Health and Human Services (234-2005-37011C).

University of Pennsylvania School of Medicine

Related Biopsy Articles from Brightsurf:

Cerebrospinal fluid as liquid biopsy for characterizing & policing of medulloblastoma
Building on previous research led by Joan Seoane, Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor, latest findings from a proof-of-concept study published in Nature Communications, show that the analysis of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA), allows for the more precise characterization, molecular diagnosis (including subtyping and risk stratification), and real time tracking of medulloblastoma (MB) - the most prevalent malignant brain tumor in childhood.

Liquid biopsy faster than tissue biopsy, improves time to treat
A pilot study comparing the effects of a liquid biopsy with tissue-based test showed that liquid biopsy turn-around time for results was approximately 10 days faster than the tissue biopsy, according to research presented today at the IASLC 2020 Lung Cancer Hot Topic: Liquid Biopsy Virtual Conference.

Study focuses on a different kind of liquid biopsy to detect cancer
In a study published August 13, 2020, in Cell by a team of collaborators from Memorial Sloan Kettering and Weill Cornell Medicine, researchers report that tiny packages of materials released by tumors, called EVPs (extracellular vesicles and particles), may serve as biomarkers for detecting a number of different types of cancer in the early stages.

Chip for liquid biopsy will help to detect prostate cancer
Researchers of Sechenov University together with their colleagues from Australia used the microfluidics technology to develop a device able to isolate cancer cells from urine of patients with prostate cancer.

Hybrid microscope could bring digital biopsy to the clinic
By adding infrared capability to the ubiquitous, standard optical microscope, researchers at the University of Illinois at Urbana-Champaign hope to bring cancer diagnosis into the digital era.

Sentinel lymph node biopsy has no benefits for stage zero breast cancer
Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS) gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.

CNIO researchers assess melanoma progression with a new liquid biopsy technique
Analysis of extracellular vesicles and circulating DNA from fluid obtained from the drainage implanted after surgery, normally disposed of as medical waste, detects melanoma patients with risk of recurrence and may help doctors decide who should undergo adjuvant therapy The new technique might change the way melanoma patients are followed up.

Contrast-enhanced MRI provides useful findings in discordant core biopsy management
An essential part of breast intervention is the process of assessing concordance between imaging findings and core biopsy results.

3D mammography significantly reduces breast biopsy rates
The use of digital breast tomosynthesis, also known as 3D mammography, may significantly reduce the number of women who undergo breast biopsy for a non-cancerous lesion following an abnormal mammogram, according to a new study.

Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to MD Anderson study
A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360®, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy.

Read More: Biopsy News and Biopsy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.